Transforming growth factor-β1 polymorphisms and graft-versus-host disease risk: a meta-analysis

Oncotarget. 2016 Jan 19;7(3):2455-61. doi: 10.18632/oncotarget.6289.

Abstract

Some studies have demonstrated that transforming growth factor (TGF)-β polymorphisms may have an important role in the pathological process of graft-versus-host disease (GVHD). However, the results are not consistent. Thus, we performed a meta-analysis. Online databases were searched to obtain relevant articles published up until May 2015. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. Donors (OR=0.56; 95%CI, 0.32-0.98; P=0.04) and recipients (OR=0.73; 95%CI, 0.63-0.85; P<0.0001) with TGF-β1 rs1800469 polymorphism showed decreased GVHD risk, respectively. Donors with TGF-β1 rs1800470 polymorphism were also observed to have lower GVHD risk (OR=0.65; 95%CI, 0.46-0.94; P=0.02). However, TGF-β1 rs1800470 polymorphism in recipients was not associated with GVHD risk (OR=1.28; 95%CI, 0.81-2.01; P=0.29). No significant heterogeneity was found in the meta-analysis. This meta-analysis suggests that donors or recipients with TGF-β1 rs1800469 polymorphism and donors with TGF-β1 rs1800470 polymorphism might be associated with reduced GVHD risk.

Keywords: TGF-β1; genetic; graft-versus-host disease; meta-analysis.

Publication types

  • Meta-Analysis

MeSH terms

  • Genetic Predisposition to Disease*
  • Graft vs Host Disease / genetics*
  • Humans
  • Polymorphism, Genetic / genetics*
  • Prognosis
  • Risk Factors
  • Transforming Growth Factor beta1 / genetics*

Substances

  • Transforming Growth Factor beta1